Drug Search Results
More Filters [+]

Oxiglutatione

Alternative Names: oxiglutatione, nov-002, navstel
Latest Update: 2022-07-25
Latest Update Note: Clinical Trial Update

Product Description

Oxiglutatione is the oxidized disulfide form of glutathione (GSH) with potential protective activity.  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Oxiglutatione)

Mechanisms of Action: Free Radical Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cellectar Biosciences
Company Location: FLORHAM PARK NJ 07932
Company CEO: JAMES V. CARUSO
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oxiglutatione

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

Phase 2: Myelodysplastic Syndrome|Preleukemia|Ovarian Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ND

P3

Completed

Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

2010-01-07

NOV002-C301

P3

Completed

Non-Small-Cell Lung Cancer

2010-01-01

31%

NOV002- IS21 -OC

P2

Completed

Ovarian Cancer

2008-05-01

NCT00960726

P2

Withdrawn

Myelodysplastic Syndrome|Preleukemia

None

Recent News Events

Date

Type

Title